Member of EFPIA's IP expert group,
Dr. Hartmann is the Head of the Corporate Patent Department for Merck KGaA. Dr. Hartmann joined Merck KGaA in 1990 and worked in the Licensing Department as well as the Business Development Unit before becoming the Head of Patent Pharmaceuticals in 2000. He is in charge of all patent affairs, including patent prosecution, maintenance and enforcement (litigation) on a corporate level for the patent department healthcare of the Merck Group. Co-chair of the Merck Access to Medicine initiative related programs such as WIPO Re:Search.
Dr. Hartmann received a degree in chemistry from the University of Giessen, Germany in 1987 and earned a PhD in chemistry from the same institution in 1990. An expert in patent law, Dr. Hartmann has lectured extensively on due diligence, patent strategy, licensing and exploitation of IP. In addition, Dr. Hartmann is a core member of Merck KGaA’s Strategic Innovation Process, a project that seeks to take products that are not part of Merck’s core business and bring them into start-up companies financed by venture capital.
He is an expert in patent law and licensing issues. His technical experiences include biotechnology, medicinal and pharmaceutical chemistry, organic chemistry as well as chemical and biochemical engineering.
His current affiliations are the following: Chairman of the Patent Group of the VfA; Berlin; Member of BDI; EFPIA and Business Europe.
Should we revisit the patent system for pharmaceutical products?
Analysis of the legal issues with the current IP system for regulated market authorisations for pharmaceutical products, as well as its economic effec